Hoxton Planning & Management LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Hoxton Planning & Management LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,813 shares of the biopharmaceutical company's stock, valued at approximately $427,000.

Several other hedge funds have also modified their holdings of GILD. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences in the first quarter worth $25,000. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences in the first quarter worth $29,000. Core Alternative Capital raised its holdings in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares during the period. IMA Advisory Services Inc. acquired a new stake in Gilead Sciences in the first quarter worth $39,000. Finally, Annis Gardner Whiting Capital Advisors LLC raised its holdings in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 216 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

GILD has been the topic of a number of research analyst reports. Oppenheimer dropped their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Morgan Stanley raised their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Finally, Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a report on Friday, July 25th. Eight research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $112.36.

Gilead Sciences Trading Up 0.8%

NASDAQ GILD traded up $0.89 on Friday, hitting $113.18. The company's stock had a trading volume of 5,016,320 shares, compared to its average volume of 5,285,206. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 1-year low of $72.43 and a 1-year high of $119.96. The company's 50-day moving average is $110.51 and its 200 day moving average is $106.80. The firm has a market cap of $140.79 billion, a PE ratio of 23.83, a PEG ratio of 0.71 and a beta of 0.33.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total transaction of $333,090.00. Following the transaction, the insider directly owned 117,168 shares of the company's stock, valued at $13,009,163.04. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at approximately $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock valued at $8,984,175. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.